Jason A. Powell
YOU?
Author Swipe
View article: Sphingosine 1-phosphate signalling in cancer stem cells
Sphingosine 1-phosphate signalling in cancer stem cells Open
Cancer stem cells (CSCs) are considered the head of a hierarchical organisation of carcinogenesis, exhibiting heightened cell survival properties, an ability to endlessly self-renew and undergo attenuated differentiation to maintain the bu…
View article: Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma
Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma Open
While three major genetic alteration subsets, characterized by mutations in STK11, KRAS , and EGFR , are seminal in driving tumorigenesis in LUAD, their distinct effects on tumor cells and the tumor microenvironment are not fully understoo…
View article: Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia
Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia Open
Despite advances in therapy, specific subtypes Acute Myeloid Leukaemia (AML) remains largely incurable. The first-in-class RNA Polymerase I (Pol I) inhibitor, CX-5461, has demonstrated promising activity in both haematological malignancies…
View article: Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukaemia
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukaemia Open
The ubiquitous metabolite heme has diverse enzymatic and signalling functions in most mammalian cells. Cells can salvage heme from the extracellular environment or synthesise heme de novo from succinyl-CoA and glycine through a series of 8…
View article: The 10th Barossa meeting: Cell Signalling to Cancer Medicine
The 10th Barossa meeting: Cell Signalling to Cancer Medicine Open
After a 2-year hiatus due to the COVID-19 pandemic we welcomed back the 10th Barossa meeting "Cell Signalling to Cancer Medicine" during November 2023 in the Barossa Valley, a world class wine producing area with exceptional cellar doors a…
View article: An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma
An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma Open
Summary While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical eval…
View article: Genome-wide transcription factor–binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs
Genome-wide transcription factor–binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs Open
Hematopoietic stem and progenitor cells (HSPCs) rely on a complex interplay among transcription factors (TFs) to regulate differentiation into mature blood cells. A heptad of TFs (FLI1, ERG, GATA2, RUNX1, TAL1, LYL1, LMO2) bind regulatory …
View article: Cell Type-Specific Regulation by a Heptad of Transcription Factors in Human Hematopoietic Stem and Progenitor Cells
Cell Type-Specific Regulation by a Heptad of Transcription Factors in Human Hematopoietic Stem and Progenitor Cells Open
Summary Hematopoietic stem and progenitor cells (HSPCs) rely on a complex interplay of transcription factors (TFs) to regulate differentiation into mature blood cells. A heptad of TFs - FLI1, ERG, GATA2, RUNX1, TAL1, LYL1, LMO2 - bind regu…
View article: Data from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression
Data from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression Open
Sphingosine kinase 2 (SK2) may have utility as a prognostic marker in inflammatory diseases such as cancer in which it has been rationalized as a candidate therapeutic target. Here, we show that SK2 has an oncogenic role in acute lymphobla…
View article: Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 9 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 9 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 9 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Data from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression
Data from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression Open
Sphingosine kinase 2 (SK2) may have utility as a prognostic marker in inflammatory diseases such as cancer in which it has been rationalized as a candidate therapeutic target. Here, we show that SK2 has an oncogenic role in acute lymphobla…
View article: Supplementary Figure 6 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 6 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 6 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Methods for Figure 1 and Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Methods for Figure 1 and Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Methods for Figure 1 and Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Methods, Figures 1 - 14, Tables 1 - 5 from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression
Supplementary Methods, Figures 1 - 14, Tables 1 - 5 from Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i>MYC</i> Expression Open
PDF file - 1070KB, Supplementary methods, Tables S1-S5 and Figures S1-S14 Table S1. Patient Information Table S2. Primers. Table S3. Regulation of c-Myc Target Genes by SK2 Inhibition Table S4. Gene Enrichment Analysis for All Nine Cell Li…
View article: Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 2 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 2 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 2 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
View article: Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers Open
Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers